Market Overview - The Hang Seng Index rose by 0.62%, gaining 148 points to close at 24,220 points, while the Hang Seng Tech Index fell by 0.27%. The early trading volume in Hong Kong was HKD 135.2 billion [1]. Copper Industry - Recent strong performance in copper prices has led institutions to believe that prices are likely to rise further. Copper mining stocks generally increased, with China Nonferrous Mining (01258) up by 2%, Zijin Mining (601899) (02899) up by 2.99%, and Jiangxi Copper (600362) (00358) up by 2.36% [1]. Cobalt Market - Luoyang Molybdenum (603993) (03993) saw a 4.14% increase, reaching a new high, as Bank of America noted that soaring cobalt prices offset the impact of extended cobalt export bans [2]. Gold Sector - Most gold stocks rose, with Shandong Gold (600547) (01787) increasing by 6.24% to reach a new peak, and Zijin Mining (02899) rising over 2.99% [3]. Banking Sector - Chinese banks' stocks experienced broad gains in early trading, with institutions indicating that H-shares are more attractive compared to A-shares. Notable increases included Minsheng Bank (600016) (01988) up by 4.72%, CITIC Bank (601998) (00998) up by 2.54%, and China Construction Bank (601939) (00939) up by 3.16% [3]. Photovoltaic Industry - The news of production cuts in photovoltaic glass has been confirmed, leading to expectations of accelerated elimination of outdated capacity in the industry. Stocks in this sector rose significantly, with Fuyao Glass (601865) (06865) up by 8.4% and Xinyi Solar (00968) up by 7.63% [3]. Beverage Sector - Nayuki's Tea (02150) surged over 35%, with a continuous two-month double-digit growth in order volume, indicating significant growth potential [4]. Food Industry - Guoquan (02517) rose over 18% after announcing plans to invest HKD 490 million in a food production base in Hainan, with institutions noting a recovery in same-store sales [5]. Jewelry Sector - Luk Fook Holdings (00590) increased by 3.99%, with institutions stating that the operational performance for the second half of the fiscal year 2025 exceeded expectations, and the company plans to resume store expansion [6]. Biotechnology Sector - JACOB-23E73 completed its first patient dosing in the U.S. for Phase I/IIa clinical trials, leading to a rise of over 7% in shares of JACOB (01167) [7]. Automotive Sector - Li Auto-W (02015) fell by 2.4%, with June delivery volumes down 24% year-on-year, following a previous downward revision of second-quarter guidance [8].

Group 1 - The Hang Seng Index rose by 0.62% while the Hang Seng Tech Index fell by 0.27% [1] - The Hong Kong solar photovoltaic sector showed strong performance, with Flat Glass rising over 9% and Xinyi Solar increasing by over 6% [1]

交银国际研究 每日晨报 2025 年 7 月 2 日 今日焦点 每月金股 七月研选：多重利好因素共振，港股进入交易顺 畅期 交银国际研究团队 近期，港股呈现盘整巩固态势。随着风险溢价回落，港股已基本完成此 前宏观影响的修复进程。在新消费、医药板块主题行情轮番推动下，恒 生指数再度逼近年内 3 月份高点。 港股正处于多重利好因素共振的有利窗口期，科技板块有望成下一轮上 涨行情重要引擎。 当前适度的拥挤度状态为投资者提供了较理想的配置窗口，特别是在科 技板块估值压力充分释放的背景下，我们认为港股从结构性行情向更为 广泛的全面上涨转换，仍需要更加强有力的基本面支撑以及政策催化因 素，以推动市场情绪的全面回暖和参与度的明显提升。 七月研选 | 全球主要指数 | | | | | --- | --- | --- | --- | | | | | 年初至今 | | | 收盘价 | 升跌% | 升跌% | | 恒指 | 24,072 | -0.87 | 20.00 | | 国指 | 8,678 | -0.96 | 19.05 | | 上 A | 3,610 | 0.59 | 2.76 | | 上 B | 258 | -0.07 ...

| 2025 年中盘点 | | | --- | --- | | 港股. | | | 板块涨跌幅排行 | | | 板块 | 区间涨跌幅 (本年初 - 2025.6.26) | | 原材料 | 52.41% | | 医疗保健 | 47.83% | | 资讯科技 | 34.38% | | 金融 | 32.11% | | 必需性消费 | 27.74% | | 非必需性消费 | 26.83% | | 电讯 | 17.48% | | 空合个业 | 16 96% | =小口 正 ㅠ 15.58% 地产建筑 13.78% 工业 7.68% 公用事业 能源 4.21% | 代码/公司名称 | 区间涨跌幅 (本年初 - 2025.6.26) | 总市值(亿港元) | | --- | --- | --- | | 03330.HK | 259.45% | 133.59 | | 灵宝黄金 | | | | 03939.HK | 154.31% | 313.77 | | 万国黄金集团 | | | | 06680.HK | 131.18% | 319.05 | | 金力永磁 | | | | 01787.HK | 129.53% | 1541 ...

基金管理人：嘉实基金管理有限公司 基金托管人：招商证券股份有限公司 二〇二五年七月 重要提示 1、嘉实中证港股通高股息投资交易型开放式指数证券投资基金发起式联接基金（以下简称"本基金"） 经中国证监会2025年6月6日证监许可〔2025〕1187号《关于准予嘉实中证港股通高股息投资交易型开放 式指数证券投资基金发起式联接基金注册的批复》注册募集。 2、本基金是契约型开放式ETF联接基金。 基金简称：嘉实中证港股通高股息投资ETF发起联接A，基金代码：024705，收取认（申）购费 基金简称：嘉实中证港股通高股息投资ETF发起联接C，基金代码：024706，不收取认（申）购费，但 从本类别基金资产中计提销售服务费 3、本基金的管理人为嘉实基金管理有限公司（以下简称"本公司"），托管人为招商证券股份有限公 司，注册登记机构为本公司。 4、本基金募集对象是符合法律法规规定的可投资于证券投资基金的个人投资者、机构投资者、合格境 外投资者和发起资金提供方以及法律法规或中国证监会允许购买证券投资基金的其他投资人。 5、本基金自2025年7月7日至2025年7月18日通过各销售机构公开发售。 6、发起资金的认购： 本基金发 ...

Group 1 - The core viewpoint is that the Hong Kong Stock Connect high dividend sector has significant allocation value during a weak US dollar cycle, benefiting from liquidity premium and enhanced EPS expectations for Chinese companies [1] - The depreciation of the US dollar reduces foreign exchange risks for foreign investors holding Hong Kong stocks, further elevating risk appetite [1] - In the current market environment, stable dividends remain a core selection, with traditional industry leaders expected to deliver improved dividend yields and ROE due to enhanced competition and weakened capital expenditure [1] Group 2 - The Hong Kong Stock Connect high dividend index, compiled by China Securities Index Co., selects 30 high dividend stocks from eligible Hong Kong-listed companies, focusing on those with good liquidity and consistent dividend payouts [1] - The index primarily covers traditional advantageous industries such as real estate and energy, reflecting the overall performance of high dividend securities in the Hong Kong market [1] - Investors without stock accounts can consider the Cathay China Securities Hong Kong Stock Connect High Dividend Investment ETF linked A (022274) and linked C (022275) [1]

Core Viewpoint - The Hang Seng High Dividend Yield Index (HSSCHKY) has shown positive performance, with significant increases in constituent stocks, indicating a favorable outlook for the banking sector and potential investment opportunities in high-dividend stocks [1][5]. Group 1: ETF Performance - The latest size of the Bosera Hang Seng High Dividend ETF (513690) reached 4.147 billion [2]. - Over the past two years, the net value of the Bosera Hang Seng High Dividend ETF has increased by 33.82%, ranking it in the top 5.90% among 2,219 index equity funds [2]. - The ETF has achieved a maximum monthly return of 24.18% since its inception, with an average monthly return of 4.96% during rising months [2]. Group 2: Risk and Return Metrics - As of June 27, 2025, the Sharpe ratio for the Bosera Hang Seng High Dividend ETF over the past year was 1.49 [3]. - The ETF has experienced a relative drawdown of 0.39% year-to-date compared to its benchmark, with a recovery period of 37 days [3]. Group 3: Fees and Tracking Accuracy - The management fee for the Bosera Hang Seng High Dividend ETF is 0.50%, and the custody fee is 0.10% [4]. - The tracking error for the ETF over the past six months was 0.069%, indicating a close alignment with the Hang Seng High Dividend Yield Index [5]. Group 4: Index Composition - The top ten weighted stocks in the Hang Seng High Dividend Yield Index account for 28.24% of the index, with notable companies including Yanzhou Coal Mining (01171) and Hang Lung Properties (00101) [5].

证券研究报告 科技 关注科技公司港股二次上市的投资机会 华泰研究 2025 年 7 月 02 日│中国内地 专题研究 科技 增持 (维持) | 黄乐平，PhD | 研究员 | | --- | --- | | SAC No. S0570521050001 | huangleping@htsc.com | | SFC No. AUZ066 | +(852) 3658 6000 | | 陈旭东 | 研究员 | | SAC No. S0570521070004 | chenxudong@htsc.com | | SFC No. BPH392 | +(86) 21 2897 2228 | | 于可熠 | 研究员 | SAC No. S0570525030001 SFC No. BVF938 行业走势图 (11) 4 20 35 50 Jul-24 Oct-24 Feb-25 Jun-25 (%) 科技 沪深300 近期，港股市场出现了 A 股已上市科技公司密集赴港二次上市的新趋势。截 至 6 月 30 日，2025 年已有包括蓝思科技、龙旗科技、豪威集团等在内 16 家 A 股半导体/消费电子公司提交了港股招股书，数量 ...

以下文章来源于申万宏源证券上海分公司 ，作者李金玲 申万宏源证券上海分公司 . 申万宏源证券上海分公司官微，能为您提供账户开立、软件下载、研究所及投顾资讯等综合服务，为您 的财富保驾护航。 数据速看： 2. 融资融券数据： 当前市场融资融券余额为18384.93亿元，较上期上升0.94%，其中融资 余额18265.53亿元，融券余额119.40亿元。本期两融日均交易额为1185.69亿元，较上期上 升9.77%，其中融资日均净买入1180.65亿元，较两周前上升9.79%，融券日均净卖出5.04 亿元，较上期上升5.54%。近两周融资净买入前三的行业分别为计算机、银行和非银金融； 融券净卖出前三的行业分别为非银金融、银行和石油石化。 3. 涨跌情况： 近两周全市场上涨家数高于下跌家数，近两周涨幅前三的行业为通信、计算机 和电子，跌幅前三的行业为美容护理、石油石化和医药生物。 4. 强弱分析： 近两周全部A股强弱分析得分为5.97，沪深300强弱分析得分5.83，创业板强 弱分析得分6.28，科创板强弱分析得分6.40，处于中性区间。 测量结果：健康 诊断说明： 本周上证综指向上突破3月高点，但当下行情距牛市启 ...

Core Insights - The core investment theme for the first half of 2025 revolves around opportunities in the Hong Kong stock market and the recovery of the pharmaceutical sector [1][2][3] Fund Performance - The top-performing fund for the first half of 2025 is the Huatai-PineBridge Hong Kong Advantage Select A, achieving a return of 85.64% [2][3] - Other notable funds include CITIC Construction Investment North Exchange Select Two-Year Open A with a return of 82.45% and Great Wall Pharmaceutical Industry Select A with a return of 75.18% [2][3] - Among the top ten funds, six are from CITIC Construction Investment, Huaxia, and Great Wall, focusing on the North Exchange or pharmaceutical sectors, all exceeding a 66% return [3] Pharmaceutical Sector Highlights - The pharmaceutical and biotechnology sectors have shown strong performance, with various funds achieving significant returns, such as the Bank of China Hong Kong Stock Connect Pharmaceutical A at 70.08% and Ping An Pharmaceutical Select A at 58.80% [4][5] - The overall pharmaceutical index has risen by 26.74% year-to-date, with the innovative drug sector outperforming, showing a year-to-date increase of 24.83% [5][6] Market Dynamics - The Hong Kong stock market, particularly in the innovative drug sector, has become a focal point for investors, with the Hong Kong Stock Connect Innovative Drug Index showing a year-to-date increase of over 60% [7][9] - The innovative drug sector is expected to continue attracting investment due to favorable policies and commercial acceleration, with significant transactions in the sector reaching $45.5 billion in the first five months of the year [6][9] Future Outlook - The investment strategy for the second half of 2025 is anticipated to focus on growth sectors, particularly innovative drugs, with three main investment themes identified: commercialization in the domestic medical insurance market, international licensing of domestic innovative drugs, and capitalizing on industry cycles and valuation opportunities [4][5] - The overall valuation of the innovative drug sector remains reasonable, providing potential opportunities for investment despite previous market corrections [5][9]